PMID- 36425577
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221126
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - New insights in ferroptosis: Potential therapeutic targets for the treatment of 
      ischemic stroke.
PG  - 1020918
LID - 10.3389/fphar.2022.1020918 [doi]
LID - 1020918
AB  - Stroke is a common disease in clinical practice, which seriously endangers 
      people's physical and mental health. The neurovascular unit (NVU) plays a key 
      role in the occurrence and development of ischemic stroke. Different from other 
      classical types of cell death such as apoptosis, necrosis, autophagy, and 
      pyroptosis, ferroptosis is an iron-dependent lipid peroxidation-driven new form 
      of cell death. Interestingly, the function of NVU and stroke development can be 
      regulated by activating or inhibiting ferroptosis. This review systematically 
      describes the NVU in ischemic stroke, provides a comprehensive overview of the 
      regulatory mechanisms and key regulators of ferroptosis, and uncovers the role of 
      ferroptosis in the NVU and the progression of ischemic stroke. We further discuss 
      the latest progress in the intervention of ferroptosis as a therapeutic target 
      for ischemic stroke and summarize the research progress and regulatory mechanism 
      of ferroptosis inhibitors on stroke. In conclusion, ferroptosis, as a new form of 
      cell death, plays a key role in ischemic stroke and is expected to become a new 
      therapeutic target for this disease.
CI  - Copyright (c) 2022 Wei, Xie, Wei, Zhao, Ren, Feng and Xu.
FAU - Wei, Ziqing
AU  - Wei Z
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, China.
AD  - Clinical Systems Biology Laboratories, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
FAU - Xie, Yi
AU  - Xie Y
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, China.
FAU - Wei, Mingze
AU  - Wei M
AD  - The Second Clinical Medical College, Harbin Medical University, Harbin, China.
FAU - Zhao, Huijuan
AU  - Zhao H
AD  - Henan International Joint Laboratory of Thrombosis and Hemostasis, Basic Medical 
      College, Henan University of Science and Technology, Luoyang, China.
FAU - Ren, Kaidi
AU  - Ren K
AD  - Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou, China.
AD  - Henan Engineering Research Center for Application & Translation of Precision 
      Clinical Pharmacy, Zhengzhou University, Zhengzhou, China.
FAU - Feng, Qi
AU  - Feng Q
AD  - Research Institute of Nephrology, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
AD  - Department of Integrated Traditional and Western Nephrology, The First Affiliated 
      Hospital of Zhengzhou University, Zhengzhou, China.
AD  - Henan Province Research Center for Kidney Disease, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, China.
FAU - Xu, Yuming
AU  - Xu Y
AD  - Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221108
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9679292
OTO - NOTNLM
OT  - ferroptosis
OT  - inhibitors
OT  - neurovascular unit (NVU)
OT  - stroke
OT  - therapeutic target
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/11/26 06:00
MHDA- 2022/11/26 06:01
PMCR- 2022/11/08
CRDT- 2022/11/25 02:49
PHST- 2022/08/16 00:00 [received]
PHST- 2022/10/26 00:00 [accepted]
PHST- 2022/11/25 02:49 [entrez]
PHST- 2022/11/26 06:00 [pubmed]
PHST- 2022/11/26 06:01 [medline]
PHST- 2022/11/08 00:00 [pmc-release]
AID - 1020918 [pii]
AID - 10.3389/fphar.2022.1020918 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Nov 8;13:1020918. doi: 10.3389/fphar.2022.1020918. 
      eCollection 2022.